Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Inhibition of LXRα/SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule.

Wang M, Sun S, Wu T, Zhang L, Song H, Hao W, Zheng P, Xing L, Ji G.

Evid Based Complement Alternat Med. 2013;2013:584634. doi: 10.1155/2013/584634. Epub 2013 May 16.

2.

[Effects of Chinese herbal medicine Jiangzhi Granule on expressions of liver X receptor α and sterol regulatory element-binding protein-1c in a rat model of non-alcoholic fatty liver disease].

Yang LL, Wang M, Liu T, Song HY, Li DF, Zheng PY, Liu P, Ji G, Ji G.

Zhong Xi Yi Jie He Xue Bao. 2011 Sep;9(9):998-1004. Chinese.

PMID:
21906525
3.

Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction.

Jin SH, Yang JH, Shin BY, Seo K, Shin SM, Cho IJ, Ki SH.

Toxicol Appl Pharmacol. 2013 Aug 15;271(1):95-105. doi: 10.1016/j.taap.2013.04.023. Epub 2013 May 5.

PMID:
23651738
4.

The efficacy and safety of traditional chinese medicine (jiang zhi granule) for nonalcoholic Fatty liver: a multicenter, randomized, placebo-controlled study.

Pan J, Wang M, Song H, Wang L, Ji G.

Evid Based Complement Alternat Med. 2013;2013:965723. doi: 10.1155/2013/965723. Epub 2013 Dec 4.

6.

Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis.

Kim YW, Kim YM, Yang YM, Kim TH, Hwang SJ, Lee JR, Kim SC, Kim SG.

Free Radic Biol Med. 2010 Feb 15;48(4):567-78. doi: 10.1016/j.freeradbiomed.2009.12.006. Epub 2009 Dec 11.

PMID:
20005944
7.

Inhibition of LXRα-dependent steatosis and oxidative injury by liquiritigenin, a licorice flavonoid, as mediated with Nrf2 activation.

Kim YW, Kim YM, Yang YM, Kay HY, Kim WD, Lee JW, Hwang SJ, Kim SG.

Antioxid Redox Signal. 2011 Mar 1;14(5):733-45. doi: 10.1089/ars.2010.3260. Epub 2010 Nov 1. Retraction in: Antioxid Redox Signal. 2012 Feb 1;16(3):292.

PMID:
20677908
8.

Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activation.

Han CY, Ki SH, Kim YW, Noh K, Lee DY, Kang B, Ryu JH, Jeon R, Kim EH, Hwang SJ, Kim SG.

Antioxid Redox Signal. 2011 Jan 15;14(2):187-202. doi: 10.1089/ars.2010.3190. Epub 2010 Sep 6.

PMID:
20560786
9.
10.

LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver.

Sim WC, Park S, Lee KY, Je YT, Yin HQ, Choi YJ, Sung SH, Park SJ, Park HJ, Shin KJ, Lee BH.

Biochem Pharmacol. 2014 Aug 15;90(4):414-24. doi: 10.1016/j.bcp.2014.06.013. Epub 2014 Jun 21.

PMID:
24955981
11.
12.

Regulation of hepatic fatty acid elongase 5 by LXRalpha-SREBP-1c.

Qin Y, Dalen KT, Gustafsson JA, Nebb HI.

Biochim Biophys Acta. 2009 Feb;1791(2):140-7. doi: 10.1016/j.bbalip.2008.12.003. Epub 2008 Dec 24.

PMID:
19136075
13.

Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition.

Wu HM, Yang YM, Kim SG.

Mol Pharmacol. 2011 Nov;80(5):859-69. doi: 10.1124/mol.111.072769. Epub 2011 Jul 29. Erratum in: Mol Pharmacol. 2012 Sep;82(3):561-2.

14.

Inhibition of liver X receptor-α-dependent hepatic steatosis by isoliquiritigenin, a licorice antioxidant flavonoid, as mediated by JNK1 inhibition.

Kim YM, Kim TH, Kim YW, Yang YM, Ryu DH, Hwang SJ, Lee JR, Kim SC, Kim SG.

Free Radic Biol Med. 2010 Dec 1;49(11):1722-34. doi: 10.1016/j.freeradbiomed.2010.09.001. Epub 2010 Sep 16.

PMID:
20840863
15.

Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-α and SREBP-1c.

Zhang J, Tan Y, Yao F, Zhang Q.

Mol Med Rep. 2012 Oct;6(4):815-20. doi: 10.3892/mmr.2012.1015. Epub 2012 Jul 31.

PMID:
22858825
16.

Effects of fish oil feeding and fasting on LXRalpha/RXRalpha binding to LXRE in the SREBP-1c promoter in mouse liver.

Nakatani T, Katsumata A, Miura S, Kamei Y, Ezaki O.

Biochim Biophys Acta. 2005 Sep 5;1736(1):77-86.

PMID:
16112614
17.

Honokiol reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element binding protein-1c and the expression of its downstream lipogenesis genes.

Yin HQ, Kim YC, Chung YS, Kim YC, Shin YK, Lee BH.

Toxicol Appl Pharmacol. 2009 Apr 1;236(1):124-30. doi: 10.1016/j.taap.2008.12.030. Epub 2009 Jan 24.

PMID:
19371623
18.

Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver.

Yamamoto T, Shimano H, Inoue N, Nakagawa Y, Matsuzaka T, Takahashi A, Yahagi N, Sone H, Suzuki H, Toyoshima H, Yamada N.

J Biol Chem. 2007 Apr 20;282(16):11687-95. Epub 2007 Feb 12.

19.

The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression.

Pawar A, Botolin D, Mangelsdorf DJ, Jump DB.

J Biol Chem. 2003 Oct 17;278(42):40736-43. Epub 2003 Aug 13.

20.

Supplemental Content

Support Center